Compass: Psychedelics Unicorn Expands Portfolio Beyond Psilocybin Into Psychedelics 2.0

Psychedelics biotech company Compass Pathways (NASDAQ: CMPS) has purchased an intellectual property portfolio that includes patent applications for a variety of psychedelic and empathogenic substances.

Compass reached unicorn status after becoming the first company in the sector to IPO on the Nasdaq last year. Compass is best known for its flagship program on psilocybin, which seeks to take the active compound in “magic mushrooms” through FDA approval for the treatment of depression and is currently in phase 2 clinical trials.

This announcement marks …

Full story available on Benzinga.com

More Compass: Psychedelics Unicorn Expands Portfolio Beyond Psilocybin Into Psychedelics 2.0